Journal Home
Search for

Volume 35, Issue 4, Pages 333-337 (April 2010)


View previous. 5 of 24 View next.

Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli

Sho TakahataaCorresponding Author Informationemail address, Takashi Idaa, Toru Hiraishia, Shiro Sakakibaraa, Kazunori Maebashia, Shinichi Teradab, Tetsuro Muratanic1, Tetsuro Matsumotoc, Chikara Nakahamad, Kazunori Tomonoe

Received 5 August 2009; accepted 19 November 2009. published online 13 January 2010.

Abstract 

To clarify the molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli, the murA, glpT, uhpT, uhpA, ptsI and cyaA genes were sequenced from six fosfomycin-resistant isolates. Two strains were found to harbour a mutation in the murA gene that leads to an amino acid substitution (Asp369Asn or Leu370Ile) in the target protein. The remaining four strains carried specific mutations in the glpT gene; one strain possessed a mutation and the other three strains possessed truncated versions of the GlpT transporter owing either to the presence of insertion sequences or a deletion in the coding region of the gene. Two of the strains with truncated GlpT had also lost the entire uhpT gene, which encodes another fosfomycin transporter. Uptake of specific substrates for the transporters was either totally blocked or reduced in strains possessing truncated forms of GlpT or those lacking the uhpT gene. Escherichia coli strains expressing an amino-acid-substituted MurA were at least eight-fold more resistant to fosfomycin than the strain overproducing wild-type MurA. In conclusion, novel amino acid substitutions in MurA or the loss of function of transporters were identified as mechanisms of fosfomycin resistance in clinical isolates of E. coli.

a Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd., 760 Morooka-cho, Kohoku-ku, Yokohama, Japan

b Product Management & Promotion Department, Pharmaceutical Marketing Division, Meiji Seika Kaisha, Ltd., 2-4-16 Kyobashi, Chuo-ku, Tokyo, Japan

c Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan

d Nakahama Clinic, Osaka, Japan

e Division of Infection Control and Prevention, Osaka University Hospital, Osaka, Japan

Corresponding Author InformationCorresponding author. Tel.: +81 45 545 3139; fax: +81 45 541 1768.

1 Present address: Department of Clinical Laboratory, Kyurin Corporation, Kitakyushu, Japan.

PII: S0924-8579(09)00545-7

doi:10.1016/j.ijantimicag.2009.11.011


View previous. 5 of 24 View next.